Innovent Biologics (Suzhou) Co. Ltd. Drug Pipeline

Innovent Biologics (Suzhou) Co. Ltd. maintains a sizable clinical portfolio, with 48 active trials out of 167 total trials registered since 2008. These active trials span from Phase 1 through Phase 4, with 18, 19, 15, and 1 trials in each phase, respectively. The portfolio covers eight therapeutic areas, but is heavily concentrated in Oncology, which accounts for 50% of active programs (24 trials). Within Oncology, the most active indications are Solid Tumor (Advanced) with eight active trials including one in Phase 3, Non-Small Cell Lung Cancer (NSCLC) with five active trials including one in Phase 3, and Melanoma with three active trials. Beyond Oncology, Innovent has a significant presence in Metabolic diseases (11 active trials), followed by Immunology (3 active trials), Cardiovascular (2 active trials), Ophthalmology (1 active trial), and Musculoskeletal (1 active trial). The weighting toward Phase 3 trials in Oncology suggests a potential focus on near-term catalysts within this therapeutic area.